AR119461A1 - Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina - Google Patents
Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidinaInfo
- Publication number
- AR119461A1 AR119461A1 ARP200102060A ARP200102060A AR119461A1 AR 119461 A1 AR119461 A1 AR 119461A1 AR P200102060 A ARP200102060 A AR P200102060A AR P200102060 A ARP200102060 A AR P200102060A AR 119461 A1 AR119461 A1 AR 119461A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- hal
- atoms
- unsubstituted
- mono
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 7
- -1 phenylene, pyridin-diyl Chemical group 0.000 abstract 4
- 125000004434 sulfur atom Chemical group 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuesto de la fórmula (1) caracterizado porque R¹ denota H, Hal, CF₃, NO₂, A, [C(R³)₂]ₙN(R³)₂, [C(R³)₂]ₙHet¹, OR³, O[C(R³)₂]ₙN(R³)₂, O[C(R³)₂]ₙS(O)ₘR³, O[C(R³)₂]ₙCOOR³, O[C(R³)₂]ₙCOON(R³)₂, O[C(R³)₂]ₙHet¹, O[C(R³)₂]ₙN(R³)Het¹, O[C(R³)₂]ₙPh o O[C(R³)₂]ₙCyc, R² denota H o CH₃, R³ denota H o A, V denota H o Hal, X denota O, o N(R³), Y denota fenileno, piridin-diilo, tiofen-diilo, 1,3-tiazol-diilo o pirazol-diilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido por Hal y/o A, Z denota CON(R³)₂, fenilo, Het⁴ o -O-A, Het¹ denota un heterociclo de 4 a 7 miembros monocíclico, aromático, insaturado o saturado que tiene de 1 a 4 átomos de N, O y/o S, que pueden no estar sustituidos o estar mono-, di- o trisustituidos por A, Hal, CN, OR³, [C(R³)₂]ₙN(R³)₂, [C(R³)₂]ₙSO₂R³, Het², oxetanilo, =NR³ y/o =O, y en los que un átomo de N puede estar oxidado, o Het¹ denota un heterociclo de 6 a 10 miembros bicíclico o espirocíclico, aromático, insaturado o saturado que tiene de 1 a 6 átomos de N, O y/o S, que pueden no estar sustituidos o estar mono-, di- o trisustituidos por A, Hal, CN, OR³, [C(R³)₂]ₙN(R³)₂, [C(R³)₂]ₙSO₂R³, Het², oxetanilo, =NR³ y/o =O, y en los que un átomo de N puede estar oxidado, Het² denota un heterociclo de 5 a 6 miembros monocíclico aromático o insaturado que tiene de 1 a 4 átomos de N, O y/o S, que pueden no estar sustituidos o estar sustituidos por A y/o Hal, o Het² denota un heterociclo de 7 a 10 miembros bicíclico aromático o insaturado que tiene de 1 a 4 átomos de N, O y/o S, que pueden no estar sustituidos o estar sustituidos por A y/o Hal, Het³ denota un heterociclo de 4 a 7 miembros monocíclico saturado que tiene de 1 a 4 átomos de N y/u O, que pueden no estar sustituidos o estar sustituidos por A, Hal, OR³ y/o =O, Het⁴ denota un heterociclo de 4 a 7 miembros monocíclico, aromático, insaturado o saturado que tiene de 1 a 4 y/o átomos de O, que pueden no estar sustituidos o estar mono-, di o trisustituidos por A, Hal, OR³, [C(R³)₂]ₙHet³, -N(R³)₂ y/o =O, o Het⁴ denota un heterociclo de 6 a 10 miembros bicíclico, aromático, insaturado o saturado que tiene de 1 a 4 y/o átomos de O, que pueden no estar sustituidos o estar mono-, di o trisustituidos por A, Hal, OR³, [C(R³)₂]ₙHet³ y/o =O, A denota alquilo no ramificado o ramificado con 1 - 10 átomos de C, en el que 1 - 3 grupos no adyacentes CH- y/o CH₂ pueden estar reemplazados por átomos O, o NH y en los que 1 - 7 átomos de H pueden estar reemplazados por R⁵, o denota (CH₂)ₙCyc, Cyc denota alquilo cíclico que tiene 3 - 7 átomos de C, R⁵ denota F, Cl, CN u OH, Ph denota fenilo, que puede no estar sustituido o estar mono-, di- o trisustituido por A, OR³ y/o Hal, Hal denota F, Cl, Br o I, m denota 0, 1 ó 2, n denota 0, 1, 2, 3 ó 4, y/o su sal, tautómero y/o estereoisómero farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19188031 | 2019-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119461A1 true AR119461A1 (es) | 2021-12-22 |
Family
ID=67438678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102060A AR119461A1 (es) | 2019-07-24 | 2020-07-23 | Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220267320A1 (es) |
| EP (1) | EP4003992A1 (es) |
| JP (2) | JP7601852B2 (es) |
| KR (2) | KR102894509B1 (es) |
| CN (2) | CN118955500A (es) |
| AR (1) | AR119461A1 (es) |
| AU (1) | AU2020318710B2 (es) |
| BR (1) | BR112022001158A2 (es) |
| CA (1) | CA3148227A1 (es) |
| IL (1) | IL289953B2 (es) |
| MX (1) | MX2022000794A (es) |
| TW (1) | TWI868186B (es) |
| WO (1) | WO2021013864A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| WO2024131742A1 (zh) * | 2022-12-20 | 2024-06-27 | 深圳湾实验室 | 一种靶向usp1的小分子抑制剂及其应用 |
| WO2025248485A1 (en) | 2024-05-31 | 2025-12-04 | Idrx, Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| WO2010132598A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
-
2020
- 2020-07-22 MX MX2022000794A patent/MX2022000794A/es unknown
- 2020-07-22 US US17/597,729 patent/US20220267320A1/en active Pending
- 2020-07-22 CN CN202411014632.3A patent/CN118955500A/zh active Pending
- 2020-07-22 CN CN202080052946.6A patent/CN114174293B/zh active Active
- 2020-07-22 JP JP2022504198A patent/JP7601852B2/ja active Active
- 2020-07-22 EP EP20750187.5A patent/EP4003992A1/en active Pending
- 2020-07-22 IL IL289953A patent/IL289953B2/en unknown
- 2020-07-22 BR BR112022001158A patent/BR112022001158A2/pt unknown
- 2020-07-22 WO PCT/EP2020/070616 patent/WO2021013864A1/en not_active Ceased
- 2020-07-22 KR KR1020227005802A patent/KR102894509B1/ko active Active
- 2020-07-22 CA CA3148227A patent/CA3148227A1/en active Pending
- 2020-07-22 KR KR1020257039581A patent/KR20250174707A/ko active Pending
- 2020-07-22 AU AU2020318710A patent/AU2020318710B2/en active Active
- 2020-07-23 TW TW109124903A patent/TWI868186B/zh active
- 2020-07-23 AR ARP200102060A patent/AR119461A1/es unknown
-
2024
- 2024-12-05 JP JP2024212157A patent/JP7730407B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL289953B2 (en) | 2025-03-01 |
| KR102894509B1 (ko) | 2025-12-02 |
| IL289953A (en) | 2022-03-01 |
| AU2020318710A1 (en) | 2022-03-10 |
| JP7601852B2 (ja) | 2024-12-17 |
| WO2021013864A1 (en) | 2021-01-28 |
| TWI868186B (zh) | 2025-01-01 |
| EP4003992A1 (en) | 2022-06-01 |
| CN114174293B (zh) | 2024-08-06 |
| CN114174293A (zh) | 2022-03-11 |
| JP7730407B2 (ja) | 2025-08-27 |
| IL289953B1 (en) | 2024-11-01 |
| KR20220041133A (ko) | 2022-03-31 |
| JP2025060626A (ja) | 2025-04-10 |
| BR112022001158A2 (pt) | 2022-05-17 |
| MX2022000794A (es) | 2022-02-16 |
| AU2020318710B2 (en) | 2025-11-20 |
| TW202118762A (zh) | 2021-05-16 |
| JP2022542072A (ja) | 2022-09-29 |
| US20220267320A1 (en) | 2022-08-25 |
| CA3148227A1 (en) | 2021-01-28 |
| CN118955500A (zh) | 2024-11-15 |
| KR20250174707A (ko) | 2025-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119461A1 (es) | Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina | |
| AR116939A1 (es) | 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR114948A1 (es) | Compuestos de benzamida | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR089424A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR100428A1 (es) | Derivados antibacterianos quinazolina-4(3h)-ona | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR118043A1 (es) | DERIVADOS DE INDAZOLIL-ISOXAZOL COMO INHIBIDORES DE c-KIT QUINASA | |
| AR093128A1 (es) | Inhibidores de la syk | |
| AR113931A1 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas | |
| AR108462A1 (es) | Derivados de piridinilo, sus composiciones farmacéuticas y usos |